Recent News from the CGRP Forum

The hottest news in migraine of the last few months – and indeed for quite some time – was the first regulatory approvals for the CGRP receptor inhibitor, Aimovig (erenumab), for migraine prevention in adults in the US and EU.

Catch up at:

Aimovig (erenumab) approved for migraine prevention in US adults »

Aimovig (erenumab) receives EU approval for migraine prevention »

From the European Academy of Neurology congress in Portugal and the International Headache Society congress in the USA came latest updates from CGRP inhibitor trials and other essential data on migraine prevention and treatment.

Catch up at:

4th Congress of the European Academy of Neurology »

American Headache Society (AHS) 60th Annual Scientific Meeting »

As the world of CGRP clinical trials never stands still, we’ve updated the clinical trials section of the Forum with additional study information on erenumab, fremanezumab, galcanezumab and eptinezumab, and we’ve introduced new trials sections for the ‘gepants’, ubrogepant, atogepant and rimegepant.

Catch up at:

Trials »

For all the other recent migraine news featured on the CGRP Forum

Catch up at: